摘要
As the first-generation tyrosine kinase inhibitor for epidermal growth factor receptor(EGFR-TKI),gefitinib has been proven effective for patients with Del19 or L858R mutations in EGFR.Secondary mutations in EGFR(mainly T790M)confer resistance to gefitinib in~50%of patients.1 However,resistance still occurs in other patients without secondary mutations in EGFR,which indicates that EGFR-independent mechanisms also play a vital role in the gefitinib resistance cascade,which deserves further investigation.
基金
supported by the National Natural Science Foundation of China(No.82102741 to L.Chang)
Young Talent Support Project of Henan Province,China(No.2024HYTP042 to L.Chang)
Henan Provincial Science and Technology Research Project(China)(No.242102310061 to L.Chang)
Shandong Provincial Natural Science Foundation(China)(No.ZR2021QH100 to X.Qi)
China Zhongguancun Precision Medicine Science and Technology Foundation(No.ZGC-YXKY-19 to L.Chang).
